The General Clinical Research Center at New York University/Bellevue Hospital Center (NYU/BHC) was one of the first 12 funded by the NIH in 1960. The goal of our GCRC is to be the focus for clinical research endeavors which elucidate the mechanisms of disease and to pioneer new therapies. The GCRC takes laboratory discoveries from the bench to the bedside and determines the safety and efficacy of new or improved modalities for treatment, diagnosis, or prevention. The mission of the NYU/BHC GCRC is to serve the sickest and poorest citizens in NYC in one of the nation's largest and oldest public hospitals and to bring the advances of modern medicine to cure or ameliorate such diseases as AIDS and cancer. The GCRC is the primary training site for clinical investigators in the physician-scientist tradition, continuation of this invaluable research and training Medicine, Pediatrics, Neurology, Psychiatry, Ob/Gyn, Environ. Medicine, Radiology and Physiology and Neuroscience. Emphasis at our GCRC is on AIDS (epidemiology, pathogenesis, treatment, virology, host response, opportunistic infections, vaccine development), tuberculosis (host factors, rapid diagnosis, modulation by cytokines), cancer (new chemotherapeutics, gene therapy strategies, radiolabeled monoclonal antibody targeting), and neuroscience (basic clinical physiology, PET scanning in schizophrenia, altering drug seeking behavior). Our GCRC embraces a molecular medicine approach to patient oriented research. Our Core Laboratory provides molecular biochemical and cellular-based assays to support these studies. More important, our vision is to create a Program for Gen Therapy within the GCRC to develop gene and DNA based therapies for cancer. AIDS and genetic metabolic disease. The Core Lab will increase its capabilities as a gene therapy assessment laboratory in order to monitor cell and gene therapy endeavors by semi-quantitative RT-PCR, in situ hybridization, and other gene and protein detection techniques. We will continue to provide expert biostatistical consultation and CDMAS support. Recruitment of a new biostatistician has allowed us to intimately involve scientific study design into each protocol. Development of a solid, exciting month-long course to teach clinical researchers the science of their field has been a highly successful training exercise over the past three years. The proposed new directions for enhanced Core Laboratory gene and DNA therapy support will provide for an exciting research environment that will keep NYU/BHC at the forefront of the molecular revolution in medicine.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
3M01RR000096-39S3
Application #
6188663
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Wilde, David B
Project Start
1975-10-01
Project End
2003-11-30
Budget Start
1999-12-01
Budget End
2000-11-30
Support Year
39
Fiscal Year
2000
Total Cost
$54,788
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Homann, O R; Misura, K; Lamas, E et al. (2016) Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. Mol Psychiatry 21:1690-1695
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-129
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Li, Yi; Tsui, Wai; Rusinek, Henry et al. (2015) Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med 56:270-3
Ghani, Mahdi; Reitz, Christiane; Cheng, Rong et al. (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol 72:1313-23
Beecham, Gary W; Dickson, Dennis W; Scott, William K et al. (2015) PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology 84:972-80

Showing the most recent 10 out of 470 publications